Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase II/III randomized double-blind placebo-controlled study of mitizodone phosphate tablets in major depressive disorder
CTR20211474Phase 3Active
- Sponsor
- HEC Pharm
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitizodone in major depressive disorder (MDD), sponsored by HEC Pharm. Started Dec 2021; status: active.
02
Drugs
mitizodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20211474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211474.